All In Biotech

Drug Trial Radar · NCT02681172

Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD

Multicenter Study to Explore the Impact of Florbetaben (FBB) in Change of Diagnosis in Patients Who Are Evaluated for AD and in Whom Lumbar Puncture is Contraindicated or CSF Results Are Ambiguous

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

218

Actual

Start

Oct 2015

Primary completion

Sep 2016

Study completion Nov 2016

Sponsor

Lead sponsor
Lantheus Biosciences Ltd.Industry
Sponsor type
Industry
First posted
Feb 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Health services research
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 4 study will explore, in the context of the present French clinical practice, the impact of florbetaben 18F (FBB) in patients evaluated for AD who require a biomarker for etiologic determination of the cognitive and functional impairment, but in whom: 1. lumbar puncture was not feasible for medical conditions 2. results of cerebrospinal fluid (CSF) analysis were considered ambiguous by treating physicians 3. lumbar puncture (LP) was refused by the patient

Conditions

  • Alzheimer's Disease (AD)

Interventions

  • Neuraceq (florbetaben 18F)Drug

    Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.

  • PETProcedure

    A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a Change of Diagnosis Comparing Pre- and Post-scan OutcomesTime frame: Visit 1 (baseline evaluation) and Visit 3 (up to 6 months later)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Coordinating center (Hôpital de La Timone) and 18 associated centers in France

    Marseille, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.